The Honest Dose #1

I'll be honest with you about why I built this.

I've always been active, played sports through high school and college, still exercise regularly, eat relatively okay. For a long time I assumed that was enough. But somewhere in the last couple of years I started seeing peptides, longevity supplements, blood testing panels, continuous glucose monitors, and recovery protocols everywhere, and a quiet fear crept in. Not that I was unhealthy, but that I was somehow behind. That by not paying attention to all of this, I was doing my future self a disservice.

At the same time, I'm aware that most of what you see online about health and wellness is noise. Bold claims, vague citations, someone selling something. The real information is out there, it just takes time to find it and even more time to evaluate it properly.

I was planning on doing that research for myself anyway. So I figured I'd share it.

That's PeptideClear, and this is The Honest Dose. Every week: one deep dive, one claim stress-tested against the research, and a few things worth watching.

Let's get into it.

If you've heard of Ozempic, you've seen what a GLP-1 drug can do. Semaglutide, the active ingredient, produces roughly 15% body weight loss in clinical trials. That was considered remarkable when it launched. Then tirzepatide (Mounjaro/Zepbound) came along targeting two hormone receptors instead of one and pushed that number to around 20%.

Retatrutide targets three.

Developed by Eli Lilly, Retatrutide is a triple hormone receptor agonist, it activates GLP-1, GIP, and glucagon receptors simultaneously. In its Phase II trial published in the New England Journal of Medicine, participants lost an average of 24% of their body weight over 48 weeks. In the highest dose group, some participants lost nearly a third of their body weight.

To put that in context: bariatric surgery typically produces 25-35% weight loss. A once-weekly injectable is approaching surgical outcomes.

It's currently in Phase III trials with results expected in the next 12-18 months. It is not FDA approved, not commercially available, and not something you can obtain through any legitimate channel right now. But if Phase III holds up, Retatrutide could become the most powerful approved weight loss medication in history.

PeptideClear is tracking its path to approval. Full profile here → peptideclear.com/peptides/retatrutide

The claim: Moderate wine consumption, a glass with dinner, protects against cardiovascular disease. Backed by decades of research.

The reality: It's more complicated than that, and the wine industry knew it.

The original studies showing heart benefits from moderate drinking had a structural flaw that took years to surface: many of the "non-drinkers" used as the comparison group weren't lifelong abstainers. They were former drinkers, people who had quit because of health problems. Sick people who stopped drinking were being compared to healthy moderate drinkers, making the drinkers look artificially healthy by comparison.

When researchers went back and separated former drinkers from lifetime abstainers, a significant portion of the cardiovascular benefit disappeared.

There's also a confounding variable nobody talks about enough: moderate drinkers tend to have higher incomes, eat better diets, exercise more, and have lower stress than both abstainers and heavy drinkers. The wine may have had nothing to do with it.

This doesn't mean wine is definitely bad for your heart. The research is genuinely contested and some newer studies with better controls still find modest benefits. What it means is that the confident version of this claim, "a glass of wine is good for you, the research is clear", was always overstated, and it was overstated in a direction that happened to benefit a $400 billion industry.

The lesson: When a health claim has a clear financial beneficiary, read the methods section.

Starting with this issue, every deep dive on PeptideClear will eventually include a Research Quality Score — a breakdown of the actual methodological strength behind a compound's evidence base.

Here's why it matters: the phrase "backed by research" is doing a lot of heavy lifting in the wellness world. A study of 12 mice and a study of 800 humans across multiple countries are both technically "research." They are not remotely the same thing.

The dimensions we're scoring:

Sample size — was the study large enough to detect a real effect, or just powered to find something statistically significant by chance?

Population diversity — who was actually in the study? A compound tested exclusively on young white men may not behave the same way in older white women or different ethnic populations. This is one of the most consistently underreported limitations in health research.

Study design — randomized controlled trial vs. observational study vs. case report. These are not equivalent. Observational studies can show correlation. Only RCTs can begin to establish causation.

Funding and conflicts of interest — industry-funded studies are not automatically wrong, but they are statistically more likely to produce positive results than independently funded studies. Knowing who paid for a study is part of evaluating it.

Replication — has the finding been reproduced by independent research groups? A single impressive study that nobody has replicated should be held lightly.

Meta-analyses — is there a synthesis of the evidence, or are we working from isolated papers?

We're building this framework out in collaboration with researchers who know this space. It'll roll out across compound profiles over the coming weeks.

Retatrutide Phase III timeline. Eli Lilly is expected to share Phase III readout signals later this year. If the data holds, this could be the biggest obesity drug approval in history. Worth watching closely.

The July 2025 peptide research conference. A significant gathering of peptide researchers is scheduled for this summer. Early abstracts suggest new data on BPC-157 human applications and GH secretagogue combinations. PeptideClear will be covering any meaningful developments.

The rise of "peptide clinics." Med spas offering peptide IV drips and injection protocols are proliferating rapidly, often with minimal medical oversight and no standardization of compounds. It's a space worth watching for both the genuine innovation and the significant risk of harm from poor sourcing and zero clinical guidance.

Most people haven't heard of it. Almost nobody is selling it on TikTok. And it has one of the strongest human evidence bases of any compound in the PeptideClear catalog.

Carnosine is a naturally occurring dipeptide, found in high concentrations in your muscles and brain, with over 120 years of research behind it. It buffers muscle acidity during exercise, acts as an antioxidant, slows protein glycation (a key driver of aging), and chelates (removes) heavy metals. Strong human RCT evidence across athletic performance, cognitive protection, skin anti-aging, and blood sugar regulation.

It's also cheap, widely available OTC, and has an excellent safety profile.

Full profile → peptideclear.com/peptides/carnosine

Hopefully that was helpful/interesting, see you next week.

-Emeka

You're receiving this because you signed up at peptideclear.com. No sponsors. No affiliate links. Just the research, translated.